Compare · ELV vs VCYT
ELV vs VCYT
Side-by-side comparison of Elevance Health Inc. (ELV) and Veracyte Inc. (VCYT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and VCYT operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.91B, about 26.0x VCYT ($3.57B).
- Both names hit the wire about 3 times in the past 4 weeks.
- VCYT has more recent analyst coverage (24 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Veracyte Inc.
- Price
- -
- -
- Market cap
- $92.91B
- $3.57B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 3
- 3
- Recent ratings
- 23
- 24
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Veracyte Inc.
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest ELV
- SEC Form 4 filed by Elevance Health Inc.
- Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
- Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
Latest VCYT
- Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
- Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
- Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
- Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
- Global Chief Commercial Off Leite John sold $160,600 worth of shares (4,015 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 124,329 units (SEC Form 4)
- Director Holstein Jens sold $204,747 worth of shares (5,000 units at $40.95) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 27,471 units (SEC Form 4)
- Veracyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
- Chief Financial Officer Chambers Rebecca sold $157,394 worth of shares (3,652 units at $43.10) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,603 shares, decreasing direct ownership by 4% to 166,025 units (SEC Form 4) (withholding tax)
- VP, Chief Accounting Officer Wygant Jonathan covered exercise/tax liability with 1,361 shares, decreasing direct ownership by 3% to 43,226 units (SEC Form 4) (for tax liability)